氯硝西泮在Wada试验中的临床价值探讨

The clinical value of clonazepam in the wada test

目的探讨氯硝西泮在Wada试验中的临床应用价值。方法回顾分析我科自2006年7月至2010年6月,准备外科治疗的106例难治性颞叶癫痫患者,用氯硝西泮替代异戊巴比妥行Wada试验。结果 106例病人均未出现明显不良反应,测试后30分钟到60分钟均基本恢复到测试前意识水平。101例通过测试者行前颞叶切除术,其中3例术后出现短暂语言迟钝,经观察脱水治疗3～7天后逐渐恢复,其余病人术后均未出现明显的语言障碍及记忆功能缺失。结论氯硝西泮在有效性、安全性上均达到临床用药要求,可以替代异戊巴比妥应用于Wada试验。

Objective To evaluate the clinical value of clonazepam replacing amobarbital in Wada test. Methods We retrospectively reviewed the clinical data of one hundred and six patients with medically intractable temporal epilepsy from July 2006 to June 2010 in our medical facility who underwent Wada test with clonazepam instead of amobarbital. Results There were no significant side effects in the 106 patients.After 30~60 minutes,all patients regained their pre-test conscious level.101 cases of them passed the test and underwent anterior temporal lobectomy.Except for three cases with temporary language barrier,the rest recovered without obvious aphasia and amnesia. Conclusion Clonazepam can meet the clinical demands with regard to drug efficacy and safety in Wada test which is a suitable alternative to amobarbital.